Results from the TRILUMINATE Pivotal trial presented at TCT 2023 adds to the growing body of evidence surrounding tricuspid valve repair in patients with severe tricuspid regurgitation (TR). In a prespecified health status analysis from the TRILUMINATE Pivotal trial, simultaneously published in JACC, Suzanne V. Arnold, MD, MHA, et al., assessed data from 350 patients with severe TR who were randomized to either tricuspid-transcatheter edge-to-edge repair (T-TEER) using the TriClip system (n=175) or medical therapy alone (n=175). Patients were assessed at baseline and at one, six and 12 months using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and mixed effects linear regression was used to compare between treatment groups.

Results from the CLASP IID trial full cohort, presented during TCT 2023 and simultaneously published in JACC: Cardiovascular Interventions, demonstrated noninferiority of mitral valve transcatheter edge-to-edge repair (M-TEER) using the PASCAL system compared with the MitraClip system in terms of safety and effectiveness in patients at prohibitive surgical risk and with significant symptomatic degenerative mitral regurgitation (DMR).

Compared with plain balloons (PB), drug-coated balloons (DCB) and, particularly, drug-eluting stents (DES) are able to reduce the need of both first and recurrent revascularizations after percutaneous treatment of drug-eluting in-stent restenosis (DES-ISR), based on a post-hoc analysis of the ISAR-DESIRE 3 trial presented during TCT 2023 and simultaneously published in JACC: Cardiovascular Interventions.

At four years, patients enrolled in the Evolut Low Risk trial who underwent TAVR continue to show "durable outcomes" for the primary endpoint of   death or disabling stroke, as well as significantly better hemodynamics, compared with patients who underwent surgical aortic valve replacement (SAVR), according to research presented during TCT 2023 and published simultaneously in JACC.